Analyzing Lisata Therapeutics (NASDAQ:LSTA) & Bioxytran (OTCMKTS:BIXT)

Lisata Therapeutics (NASDAQ:LSTA) and Bioxytran (OTCMKTS:BIXT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk and valuation.

Volatility & Risk

Lisata Therapeutics has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, Bioxytran has a beta of 1.93, suggesting that its stock price is 93% more volatile than the S&P 500.

Profitability

This table compares Lisata Therapeutics and Bioxytran’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lisata Therapeutics	N/A	-79.04%	-65.79%
Bioxytran	N/A	N/A	-1,510.01%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Lisata Therapeutics and Bioxytran, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lisata Therapeutics	1	1	2	0	2.25
Bioxytran	0	0	0	0	0.00

Lisata Therapeutics presently has a consensus target price of $23.50, indicating a potential upside of 1,052.53%. Given Lisata Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Lisata Therapeutics is more favorable than Bioxytran.

Insider & Institutional Ownership

8.9% of Lisata Therapeutics shares are held by institutional investors. 9.6% of Lisata Therapeutics shares are held by insiders. Comparatively, 70.0% of Bioxytran shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Lisata Therapeutics and Bioxytran”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lisata Therapeutics	$1.00 million	17.98	-$19.99 million	($2.13)	-0.96
Bioxytran	N/A	N/A	-$2.37 million	($0.03)	-2.66

Bioxytran has lower revenue, but higher earnings than Lisata Therapeutics. Bioxytran is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Lisata Therapeutics beats Bioxytran on 7 of the 12 factors compared between the two stocks.

About Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

About Bioxytran

Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was founded in 2008 and is headquartered in Needham, Massachusetts.